These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 28322294

  • 1. Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials.
    Lyu X, Zhu X, Zhao B, Du L, Chen D, Wang C, Liu G, Ran X.
    Sci Rep; 2017 Mar 21; 7():44865. PubMed ID: 28322294
    [Abstract] [Full Text] [Related]

  • 2. The effects of incretin-based therapies on β-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials.
    Wu S, Gao L, Cipriani A, Huang Y, Yang Z, Yang J, Yu S, Zhang Y, Chai S, Zhang Z, Sun F, Zhan S.
    Diabetes Obes Metab; 2019 Apr 21; 21(4):975-983. PubMed ID: 30536884
    [Abstract] [Full Text] [Related]

  • 3. Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.
    Takahashi M, Shibasaki M, Echizen H, Kushiyama A.
    PLoS One; 2020 Apr 21; 15(7):e0236603. PubMed ID: 32706828
    [Abstract] [Full Text] [Related]

  • 4. Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis.
    Cai X, Yang W, Zhou L, Zhang S, Han X, Ji L.
    Endocrine; 2015 Dec 21; 50(3):590-7. PubMed ID: 26048437
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y, Hong T.
    Diabetes Obes Metab; 2014 Feb 21; 16(2):111-7. PubMed ID: 23668534
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis.
    Cai X, Han X, Luo Y, Ji L.
    J Diabetes; 2015 May 21; 7(3):347-59. PubMed ID: 25043156
    [Abstract] [Full Text] [Related]

  • 9. Short-term and long-term effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta-analysis of randomized controlled trials.
    Li R, Wang R, Li H, Sun S, Zou M, Cheng G.
    Diabetes Metab Res Rev; 2016 Sep 21; 32(6):460-9. PubMed ID: 26433213
    [Abstract] [Full Text] [Related]

  • 10. Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis.
    Gao W, Wang Q, Yu S.
    J Endocrinol Invest; 2016 Sep 21; 39(9):1061-74. PubMed ID: 27072669
    [Abstract] [Full Text] [Related]

  • 11. Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Bae JH, Kim S, Park EG, Kim SG, Hahn S, Kim NH.
    Endocrinol Metab (Seoul); 2019 Mar 21; 34(1):80-92. PubMed ID: 30912341
    [Abstract] [Full Text] [Related]

  • 12. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
    Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, Cobelli C, Stein PP.
    Diabetes Obes Metab; 2008 Dec 21; 10(12):1212-20. PubMed ID: 18476982
    [Abstract] [Full Text] [Related]

  • 13. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
    Yang J, Huang C, Wu S, Xu Y, Cai T, Chai S, Yang Z, Sun F, Zhan S.
    PLoS One; 2017 Dec 21; 12(12):e0187537. PubMed ID: 29206832
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K, Gräber S.
    Diabetes Obes Metab; 2012 Dec 21; 14(12):1061-72. PubMed ID: 22519906
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL, Degeeter M, Nuzum DS, Tzefos M.
    Ann Pharmacother; 2013 Apr 21; 47(4):490-505. PubMed ID: 23548652
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis.
    Liu X, Men P, Wang B, Cai G, Zhao Z.
    Lipids Health Dis; 2019 Jun 18; 18(1):144. PubMed ID: 31208420
    [Abstract] [Full Text] [Related]

  • 20. Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: A systematic review and meta-analysis of controlled trials.
    Atkin SL, Katsiki N, Banach M, Mikhailidis DP, Pirro M, Sahebkar A.
    J Diabetes Complications; 2017 Sep 18; 31(9):1458-1464. PubMed ID: 28647512
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.